<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">107696</article-id>
<article-id pub-id-type="doi">10.7554/eLife.107696</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107696.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Cell Biology</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Immunology and Inflammation</subject>
</subj-group>
</article-categories><title-group>
<article-title>The Anti-Inflammatory Role of GPNMB in Post-Traumatic Osteoarthritis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Al-Adlaan</surname>
<given-names>Asaad A</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cook</surname>
<given-names>Bryson</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ernesto</surname>
<given-names>Solorzano Z</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hussein</surname>
<given-names>Nazar J</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaber</surname>
<given-names>Fatima A</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2050-755X</contrib-id>
<name>
<surname>Kronk</surname>
<given-names>Trinity</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frangiamore</surname>
<given-names>Salvatore</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ball</surname>
<given-names>Hope C</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2857-6936</contrib-id>
<name>
<surname>Safadi</surname>
<given-names>Fayez F</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a7">7</xref>
<email>fsafadi@neomed.edu</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q9qf557</institution-id><institution>Department of Biomedical Sciences, Northeast Ohio Medical University</institution></institution-wrap>, <city>Rootstown</city>, <country country="US">United States</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/049pfb863</institution-id><institution>Biomedical Sciences Program, Kent State University</institution></institution-wrap>, <city>Kent</city>, <country country="US">United States</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q9qf557</institution-id><institution>Musculoskeletal Research Group, NEOMED</institution></institution-wrap>, <city>Rootstown</city>, <country country="US">United States</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0107t3e14</institution-id><institution>Rebecca D. Considine Research Institute, Akron Children’s Hospital</institution></institution-wrap>, <city>Akron</city>, <country country="US">United States</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01x6q1934</institution-id><institution>Cleveland Clinic Foundation</institution></institution-wrap>, <city>Cleveland</city>, <country country="US">United States</country></aff>
<aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q9qf557</institution-id><institution>Basic and Translational Biomedicine Program, Northeast Ohio Medical University</institution></institution-wrap>, <city>Rootstown</city>, <country country="US">United States</country></aff>
<aff id="a7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130jk839</institution-id><institution>University Hospitals</institution></institution-wrap>, <city>Cleveland</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Abu-Amer</surname>
<given-names>Yousef</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Washington University in St. Louis</institution>
</institution-wrap>
<city>St Louis</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Huang</surname>
<given-names>Christopher L-H</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Cambridge</institution>
</institution-wrap>
<city>Cambridge</city>
<country country="GB">United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-07-31">
<day>31</day>
<month>07</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP107696</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-06-07">
<day>07</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-06-09">
<day>09</day>
<month>06</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.06.06.658389"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Al-Adlaan et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Al-Adlaan et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-107696-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>Osteoactivin (GPNMB) is a transmembrane protein expressed in multiple cell types with known functions in muscle, bone, and neurons, but the role of GPNMB in chondrocytes and cartilage homeostasis remains unknown. Here we show GPNMB is expressed in human and mouse primary chondrocytes, and that its expression is increased in damaged human cartilage and under pro-inflammatory conditions. We report that recombinant GPNMB treatment inhibits the expression of Mmps, Adamts-4 and Il-6 following IL-1β-stimulation <italic>in vitro. In vivo</italic>, GPNMB function was assessed in a post-traumatic osteoarthritis model, destabilization of the medial meniscus (DMM). Transgenic animals lacking functional GPNMB protein (DBA/2J) developed severe cartilage damage and demonstrated significant increases in pro-inflammatory cytokine expression following DMM. To elucidate the mechanism of action, we demonstrate that GPNMB regulates the MAPK signaling pathway in primary murine chondrocytes. Taken together, our results identify a novel anti-inflammatory role for GPNMB in cartilage and chondrocytes and identify GPNMB as a potential therapeutic modality for inflammatory joint diseases.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>GPNMB</kwd>
<kwd>Osteoarthritis</kwd>
<kwd>Cartilage</kwd>
<kwd>MAPK</kwd>
<kwd>DMM</kwd>
<kwd>Inflammation</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>

</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Osteoactivin, also known as glycoprotein non-metastatic melanoma protein B (GPNMB), is a transmembrane glycoprotein first identified in a rat model of osteopetrosis (<xref ref-type="bibr" rid="c55">Safadi et al., 2002</xref>). GPNMB has subsequently been found in many cell types including osteoblasts, osteoclasts, macrophages, hepatocytes, dendritic cells and cancer cells and is known to be involved in a plethora of functions including proliferation, differentiation, migration, angiogenesis, osteogenesis, and apoptosis (<xref ref-type="bibr" rid="c8">Arosarena et al., 2018</xref>; <xref ref-type="bibr" rid="c52">Rose et al., 2010</xref>; <xref ref-type="bibr" rid="c61">Schwarzbich et al., 2012</xref>; <xref ref-type="bibr" rid="c62">Selim et al., 2003</xref>; <xref ref-type="bibr" rid="c63">Sheng et al., 2008</xref>; <xref ref-type="bibr" rid="c71">Yu et al., 2016</xref>). GPNMB encodes a 574 amino acid protein that includes an arginine-glycine-aspartic acid (RGD) domain, a polycystic kidney disease domain (PKD) and a proline rich repeat (PRRD) domain (<xref ref-type="fig" rid="figS1">Supplemental figure 1</xref>) (<xref ref-type="bibr" rid="c47">Owen et al., 2003</xref>). The majority of the biological function, however, is conducted by the extracellular domain of the protein, shed from the surface by furin-like proteases and extracellular proteases, such as a disintegrin and metalloproteinase with thrombospondin motifs-10 (Adamts-10) (<xref ref-type="bibr" rid="c35">Kawahara et al., 2016</xref>; <xref ref-type="bibr" rid="c44">Murata et al., 2015</xref>; <xref ref-type="bibr" rid="c48">Oyewumi et al., 2016</xref>; <xref ref-type="bibr" rid="c52">Rose et al., 2010</xref>).</p>
<p>The role of GPNMB in fracture repair and bone regeneration is well studied. Upregulated in response to skeletal damage, GPNMB promotes bone formation through either direct or indirect regulation of osteoblast proliferation and adhesion through multiple signaling pathways (<xref ref-type="bibr" rid="c1">Abdelmagid et al., 2010</xref>; <xref ref-type="bibr" rid="c2">Abdelmagid et al., 2008</xref>; <xref ref-type="bibr" rid="c4">Abdelmagid et al., 2015</xref>; <xref ref-type="bibr" rid="c16">Frara et al., 2016</xref>). GPNMB also functions as a negative regulator of osteoclast differentiation and survival (<xref ref-type="bibr" rid="c4">Abdelmagid et al., 2015</xref>; <xref ref-type="bibr" rid="c63">Sheng et al., 2008</xref>; <xref ref-type="bibr" rid="c64">Sondag et al., 2016</xref>). Indeed, transgenic GPNMB mice exhibit increased bone volume, mineralization and thickness, increased osteoblast number and decreased osteoclast survival compared to C57BL/6 control animals (<xref ref-type="bibr" rid="c4">Abdelmagid et al., 2015</xref>; <xref ref-type="bibr" rid="c16">Frara et al., 2016</xref>; <xref ref-type="bibr" rid="c64">Sondag et al., 2016</xref>).</p>
<p>GPNMB is emerging as a crucial factor in the inflammatory response following tissue injury (<xref ref-type="bibr" rid="c36">Li et al., 2010</xref>). GPNMB levels were elevated in both mouse and rat models after myocardial infarction (<xref ref-type="bibr" rid="c31">Järve et al., 2017</xref>). GPNMB has also been shown to have an anti-inflammatory role in macrophages, reducing the expression of pro-inflammatory signaling molecules such as interleukin-6 (IL-6), interleukin-12p40 (IL-12p40) and nitric oxide (NO) (<xref ref-type="bibr" rid="c36">Li et al., 2010</xref>; <xref ref-type="bibr" rid="c50">Ripoll et al., 2007</xref>; <xref ref-type="bibr" rid="c72">Zhou et al., 2017</xref>). Furthermore, GPNMB has been shown to play a role in the synthesis of extracellular matrix (ECM) components and its expression is increased with inflammatory stimuli and ECM damage, conditions common in the pathophysiology of degenerative joint diseases such as osteoarthritis (OA) (<xref ref-type="bibr" rid="c33">Jiang et al., 2011</xref>; <xref ref-type="bibr" rid="c47">Owen et al., 2003</xref>; <xref ref-type="bibr" rid="c55">Safadi et al., 2002</xref>; <xref ref-type="bibr" rid="c66">Sun et al., 2015</xref>). Despite the above roles, the biological function of GPNMB in normal or damaged cartilage and chondrocyte homeostasis have not yet been studied.</p>
<p>To address this knowledge gap, we first determined GPNMB expression in human primary chondrocytes and cartilage. GPNMB expression was increased in damaged cartilage from osteoarthritic patients compared to normal (no history of rheumatic disease) and following pro-inflammatory stimulus in human primary chondrocytes and cell-lines. Furthermore, recombinant GPNMB treatment significantly lowered expression of catabolic markers in human primary chondrocytes and reduced ECM degradation in cartilage explants. We subsequently validated these results in murine primary chondrocytes and examined endogenous GPNMB expression in a mouse model: DBA/2J mice, which produce a truncated and non-functional GPNMB protein (<xref ref-type="bibr" rid="c3">Abdelmagid et al., 2014</xref>). To better understand the role of GPNMB <italic>in vivo</italic>, we induced post-traumatic OA via destabilization of the medial meniscus (DMM) surgery in DBA/2J mice (<xref ref-type="bibr" rid="c14">Culley et al., 2015</xref>; <xref ref-type="bibr" rid="c19">Glasson et al., 2007</xref>). The results demonstrated functional GPNMB is essential for the reduction of inflammation and protection against post-traumatic cartilage damage. Collectively, our results are the first to show the extracellular domain of GPNMB serves an anti-inflammatory function in primary chondrocytes and cartilage and reduces catabolic gene expression both <italic>in vitro</italic> and <italic>in vivo</italic> and suggests GPNMB may be a potential anti-inflammatory therapy for inflammatory joint diseases.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>GPNMB expression is elevated in damaged human cartilage</title>
<p>We first assessed the expression levels of GPNMB in human OA cartilage samples. To confirm we had accurately harvested cartilage from regions of both low- and high-grade OA damage, we began by first macroscopically evaluating the cartilage using India Ink, where particles adhere to fibrillated tissue indicative of cartilage damage (<xref ref-type="bibr" rid="c59">Schmitz et al., 2010</xref>). Cartilage was isolated from low- and high-grade cartilage samples for mRNA analyses. We examined expression levels of a key cartilage ECM component, aggrecan (ACAN). Expression levels of ACAN were significantly decreased in high-grade OA cartilage compared to low-grade regions supporting our assessment of cartilage damage (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). We then determined expression levels of GPNMB in cartilage harvested from the low-grade and high-grade OA cartilage. Results demonstrated a significant increase in GPNMB expression in high-grade cartilage versus low-grade cartilage levels (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). This data and previous findings regarding the anti-inflammatory role of GPNMB in other cell types led us to postulate that GPNMB has an anti-inflammatory role in primary chondrocytes.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1:</label>
<caption><title>GPNMB expression is increased in high-grade OA cartilage and recombinant GPNMB reduces catabolic gene expression in human HTB-94 cell culture and cartilage damage in human cartilage explants.</title>
<p>Human articular cartilage was isolated from low-grade and high-grade OA joints and mRNA expression of (<bold>A</bold>) ACAN and (<bold>B</bold>) GPNMB were determined via RT-qPCR. HTB-94 cells treated with combination of recombinant GPNMB and IL-1β demonstrated significantly decreased expression of (<bold>C</bold>) Mmp-9 (<bold>D</bold>) Mmp-13 and (<bold>E</bold>) IL-6 mRNAs. Combined recombinant GPNMB and IL-1β treatment significantly reduced cartilage degradation in human explant cultures compared to IL-1β treatment alone in Safranin-O-stained human cartilage explants (<bold>F</bold>). Scale bar= 200µm in top panels and 100µm in magnified lower images. Data presented as Mean ± SEM (n=7). **= p&lt;0.01, ***=p&lt;0.001, ****=p&lt;0.0001.</p></caption>
<graphic xlink:href="658389v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>GPNMB treatment reduces catabolic gene expression in IL-1β stimulated HTB-94 chondrocytes</title>
<p>One of the hallmarks of OA is increased inflammation within the joint and an increase in the production of inflammatory chemokines and cytokines such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase -13 (MMP-13) (<xref ref-type="bibr" rid="c18">Gauci et al., 2017</xref>; <xref ref-type="bibr" rid="c22">Goldring, 2012</xref>; <xref ref-type="bibr" rid="c25">Goldring &amp; Goldring, 2004</xref>; <xref ref-type="bibr" rid="c51">Robinson et al., 2016</xref>). Since GPNMB was shown to be elevated in more damaged regions of human cartilage, we theorized that increased GPNMB levels may serve a protective anti-inflammatory role. To test this, we utilized human chondrosarcoma cells (HTB-94) which maintain a chondrocyte phenotype in culture and have been established as an appropriate model for examinations of inflammation and inflammatory signaling pathways (<xref ref-type="bibr" rid="c42">Mengshol et al., 2001</xref>). Cells were serum starved overnight and then either left untreated or treated for 24 hours with either recombinant GPNMB alone, IL-1β alone or a combination of recombinant GPNMB and IL-1β. As expected, IL-1β treatment significantly increased expression of Mmp-9, Mmp-13 and Il-6 (<xref rid="fig1" ref-type="fig">Figure 1C-E</xref>). Interestingly, treatment with recombinant GPNMB alone significantly decreased gene expression of both Mmp-13 and Il-6 and inclusion of GPNMB with IL-1β reduced catabolic expression of all target genes (<xref rid="fig1" ref-type="fig">Figure 1C-E</xref>). Together, this suggests GPNMB has an anti-inflammatory role in human primary chondrocytes.</p>
</sec>
<sec id="s2c">
<title>Human explant cultures treated with GPNMB display low ECM degradation after IL-1β stimulation</title>
<p>Having determined catabolic gene expression was reduced with recombinant GPNMB treatment in HTB-94 chondrocytes, we next determined if GPNMB pharmacological treatment could reduce ECM degradation following IL-1β stimulation <italic>ex vivo</italic> in human explant cultures. Undamaged human explants were serum starved overnight then left untreated or treated for 24 hours with recombinant GPNMB alone, IL-1β alone or a combination of recombinant GPNMB and IL-1β. Safranin-O-stained explant results showed severe ECM degradation in cultures treated with IL-1β alone compared to untreated controls (<xref rid="fig1" ref-type="fig">Figure 1F</xref>). Additionally, the severity of the degradation was reduced with the inclusion of recombinant GPNMB (<xref rid="fig1" ref-type="fig">Figure 1F</xref>). These results establish that recombinant GPNMB treatment decreases IL-1β-induced inflammation in human chondrocytes and cartilage.</p>
</sec>
<sec id="s2d">
<title>IL-1β stimulation induces Gpnmb expression in murine primary chondrocytes</title>
<p>Examinations of endogenous expression of GPNMB in human cartilage and chondrocytes demonstrated that GPNMB expression was upregulated in high-grade damaged OA cartilage and following IL-1β proinflammatory stimulation in human primary chondrocytes. Next, we confirmed these results in murine primary chondrocytes. Primary chondrocytes were isolated from 5-6 day old pups (n=6) as previously described and serum starved overnight (<xref ref-type="bibr" rid="c27">Gosset et al., 2008</xref>; <xref ref-type="bibr" rid="c34">Jonason et al., 2015</xref>). The chondrocytes were then treated, in triplicate, with either regular culture media (control) or IL-1β for 24 hours and the expression of Gpnmb was determined via RT-qPCR. Results showed a significant increase in GPNMB expression following IL-1β stimulation compared to untreated controls (<xref rid="fig2" ref-type="fig">Figure 2A</xref>).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2:</label>
<caption><title>Gpnmb expression is induced with IL-1β proinflammatory stimulation, reduced in DBA/2J mice and recombinant GPNMB inhibits catabolic expression in DBA/2J GPNMB<sup>+</sup> and DBA/2J chondrocytes.</title>
<p>(<bold>A</bold>) Gpnmb expression is increased with pro-inflammatory IL-1β treatment. Gpnmb expression (<bold>B</bold>) and protein (<bold>C, D</bold>) is significantly reduced in DBA/2J mice. Recombinant GPNMB treatment does not affect chondrocyte proliferation (<bold>E</bold>) or viability (<bold>F</bold>). Recombinant GPNMB inhibits Mmp-3, Mmp-9, Mmp-13 expression in DBA/2J GPNMB<sup>+</sup> (<bold>G-I</bold>) and DBA/2J (<bold>J-L</bold>) chondrocytes and reduces Adamts-4 (<bold>M</bold>,<bold>N</bold>) and IL-6 (<bold>O</bold>,<bold>P</bold>) expression. Scale bar= 200µm. Data presented as Mean ± SEM (n=6). *=p&lt;0.05, **= p&lt;0.01, ***=p&lt;0.001, ****=p&lt;0.0001.</p></caption>
<graphic xlink:href="658389v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2e">
<title>Endogenous Gpnmb is reduced in DBA/2J mutant mice</title>
<p>To study the role of GPNMB in chondrocytes, we utilized a mouse model with a natural mutation in GPNMB (DBA/2J). This global mouse model produces a truncated and non-functional GPNMB protein (<xref ref-type="bibr" rid="c3">Abdelmagid et al., 2014</xref>). For this experiment, we determined endogenous Gpnmb levels in primary chondrocytes of DBA/2J GPNMB<sup>+</sup> (control) and DBA/2J mice. Results revealed Gpnmb mRNA levels in the mutant DBA/2J mice (n=6) were significantly lower than those found in DBA/2J GPNMB<sup>+</sup> (n=6) chondrocytes (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). We next confirmed these results via immunohistochemical (IHC) analyses of DBA/2J GPNMB<sup>+</sup> and DBA/2J articular cartilage using an anti-GPNMB antibody. Joint sections from DBA/2J GPNMB<sup>+</sup> and DBA/2J mice were used to visualize and quantify the presence of GPNMB in joints of both mouse models and results showed significantly fewer GPNMB positive cells in DBA/2J mice (<xref rid="fig2" ref-type="fig">Figure 2C, D</xref>).</p>
</sec>
<sec id="s2f">
<title>Recombinant GPNMB treatment does not affect murine chondrocyte viability or proliferation</title>
<p>Before investigating the effects of GPNMB on murine chondrocytes <italic>in vitro</italic>, we first determined if pharmacological treatment with recombinant GPNMB would affect primary chondrocyte viability or proliferation. Chondrocytes were cultured with increasing doses of GPNMB for 72 hours, and cell viability and proliferation were assessed with MTT and CyQuant assays, respectively. Data revealed no significant changes in chondrocyte viability or proliferation with increasing concentrations of recombinant GPNMB (<xref rid="fig2" ref-type="fig">Figure 2E, F</xref>). These results suggest that treatment has no adverse or toxic effects on chondrocytes.</p>
</sec>
<sec id="s2g">
<title>GPNMB treatment inhibits Mmp, Adamts-4 and Il-6 expression in DBA/2J GPNMB<sup>+</sup> and DBA/2J chondrocytes</title>
<p>To determine if treatment with recombinant GPNMB would alter catabolic gene expression in murine primary chondrocytes, we isolated femoral and tibial articular cartilage from 5-6 day old male control DBA/2J GPNMB<sup>+</sup> (n=6) and mutant DBA/2J mouse pups (n=6) and plated the primary chondrocytes of each mouse model in triplicate. Before treatment, we examined endogenous mRNA levels of Mmp-3, Mmp-9 and, Mmp-13in control DBA/2J GPNMB<sup>+</sup> and DBA/2J primary chondrocytes. Results found no significant differences in endogenous mRNA expression in these strains (<xref ref-type="fig" rid="figS2">Supplemental figure 2</xref>). The isolated chondrocytes were serum starved overnight and either left untreated (control) or treated with recombinant GPNMB alone, IL-1β alone or a combination of IL-1β and recombinant GPNMB for 24 hours. Expression levels of cartilage-degrading metalloproteinases Mmp-3, Mmp-9 and Mmp-13 were determined via RT-qPCR analysis.</p>
<p>In DBA/2J GPNMB<sup>+</sup> mice, results showed mRNA levels of Mmp-3, Mmp-9 and Mmp-13 were not significantly different between untreated chondrocytes and those treated with recombinant GPNMB alone (<xref rid="fig2" ref-type="fig">Figure 2G-I</xref>). Whereas chondrocytes treated with IL-1β alone showed significant upregulation of Mmp-3, Mmp-9, and Mmp-13 (<xref rid="fig2" ref-type="fig">Figure 2G-I</xref>). Interestingly, when DBA/2J GPNMB<sup>+</sup> chondrocytes were treated with a combination of IL-1β and recombinant GPNMB results demonstrated expression of all three catabolic markers were significantly reduced, suggesting that GPNMB might play a role as an anti-inflammatory factor in chondrocytes (<xref rid="fig2" ref-type="fig">Figure 2G-I</xref>).</p>
<p>Mutant DBA/2J primary chondrocyte results showed no significant differences in Mmp-3, Mmp-9 or Mmp-13 expression between untreated cells and those treated with GPNMB alone (<xref rid="fig2" ref-type="fig">Figure 2J-L</xref>). Chondrocytes treated with IL-1β alone demonstrated significant increases in Mmp-3, Mmp-9 and Mmp-13 mRNA levels (<xref rid="fig2" ref-type="fig">Figure 2J-L</xref>). Interestingly, these increases were significantly higher in DBA/2J animals compared to fold changes seen in chondrocytes from DBA/2J GPNMB<sup>+</sup> controls (<xref rid="fig2" ref-type="fig">Figure 2G-I</xref>). Primary DBA/2J chondrocytes treated with the combination of IL-1β and recombinant GPNMB showed significant reduction in IL-1β-stimulated increased in Mmp-3, Mmp-9 and Mmp-13 expression (<xref rid="fig2" ref-type="fig">Figure 2J-L</xref>). Together, these results indicate GPNMB has anti-inflammatory functions and reduces expression of IL-1β-stimulated matrix metalloproteinases.</p>
<p>In addition to Mmps, which target and degrade ECM collagens, we also evaluated whether recombinant GPNMB would affect expression of Il-6 and an ACAN degrading enzyme, Adamts-4, in DBA/2J GPNMB<sup>+</sup> and DBA/2J primary chondrocytes. First, we evaluated endogenous levels of Adamts-4 and Il-6 in DBA/2J GPNMB<sup>+</sup> and DBA/2J primary chondrocytes and found no significant differences in mRNA expression between the strains (<xref ref-type="fig" rid="figS2">Supplemental figure 2</xref>). Then, to study the effects recombinant GPNMB treatment on Adamts-4 and Il-6 expression, primary chondrocytes from both strains were serum starved overnight prior to treatment with recombinant GPNMB alone, IL-1β alone or a combination of IL-1β and recombinant GPNMB for 24 hours.</p>
<p>First, we examined Adamts-4 mRNA expression in DBA/2J GPNMB<sup>+</sup> chondrocytes (n=6). Results showed that treatment with recombinant GPNMB alone was sufficient to significantly reduce Adamts-4 mRNA expression in treated chondrocytes compared to untreated controls (<xref rid="fig2" ref-type="fig">Figure 2M</xref>). Treatment with IL-1β alone significantly increased expression of Adamts-4, while treatment with recombinant GPNMB and IL-1β significantly reduced Adamts-4 expression in DBA/2J GPNMB<sup>+</sup> chondrocytes (<xref rid="fig2" ref-type="fig">Figure 2M</xref>). In chondrocytes derived from DBA/2J mice (n=6), treatment with recombinant GPNMB alone significantly reduced Adamts-4 expression compared to untreated controls, while IL-1β treatment alone significantly increased Adamts-4 expression (<xref rid="fig2" ref-type="fig">Figure 2N</xref>). Treatment with the combination of recombinant GPNMB and IL-1β significantly reduced Adamts-4 levels in treated chondrocytes (<xref rid="fig2" ref-type="fig">Figure 2N</xref>).</p>
<p>Next, we assessed mRNA expression of Il-6 in primary chondrocytes isolated from DBA/2J GPNMB<sup>+</sup> and DBA/2J mice (n=6, each strain). In both strains, recombinant GPNMB treatment alone resulted in no significant difference in Il-6 mRNA compared to expression untreated controls (<xref rid="fig2" ref-type="fig">Figure 2O, P</xref>). Similarly, IL-1β treatment alone significantly increased Il-6 expression in chondrocytes of both mouse strains (<xref rid="fig2" ref-type="fig">Figure 2O, P</xref>). Results also revealed that IL-1β-induced expression of proinflammatory Il-6 was significantly higher (a 9-fold) in mutant DBA-2J mice than in DBA/2J GPNMB<sup>+</sup> control animals. Furthermore, when treated with IL-1β and recombinant GPNMB Il-6 expression was significantly reduced in DBA/2J GPNMB<sup>+</sup> chondrocytes (4-fold) and in those from DBA/2J (9-fold) mice with reduction significantly higher than those of controls (<xref rid="fig2" ref-type="fig">Figure 2O, P</xref>). Together, these results indicate GPNMB has an anti-inflammatory effect in murine primary chondrocytes by reducing expression of both Adamts-4 and Il-6.</p>
</sec>
<sec id="s2h">
<title>Recombinant GPNMB treatment does not alter anabolic gene expression</title>
<p>Having determined that recombinant GPNMB treatment lowered IL-1β-induced catabolic gene expression in human and mouse primary chondrocytes, we next assessed if GPNMB would affect anabolic gene expression. We began by first determining endogenous mRNA levels of anabolic genes SRY-Box Transcription Factor 9 (Sox-9), type-II collagen (Col2α1) and Acan in DBA/2J GPNMB<sup>+</sup> and DBA/2J chondrocytes. Results determined no significant difference in gene expression (<xref ref-type="fig" rid="figS3">Supplemental figure 3</xref>). To determine the effect of recombinant GPNMB on primary chondrocytes, the cells were serum starved overnight and then treated for 24 hours with either media (control), recombinant GPNMB alone, IL-1β alone or a combination of IL-1β and recombinant GPNMB. mRNA expression was assessed via RT-qPCR.</p>
<p>Results in DBA/2J GPNMB<sup>+</sup> chondrocytes (n=6) showed recombinant GPNMB treatment alone did not significantly alter anabolic gene expression compared to untreated control cells (<xref rid="fig3" ref-type="fig">Figure 3A, B, C</xref>). Chondrocytes treated with IL-1β alone demonstrated a significant decrease in Sox-9, Col2a1 and ACAN mRNA expression (<xref rid="fig3" ref-type="fig">Figure 3A, B, C</xref>). Interestingly, the combined treatment of recombinant GPNMB and IL-1β showed no significant effects on anabolic gene expression (<xref rid="fig3" ref-type="fig">Figure 3A, B, C</xref>).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3:</label>
<caption><title>Recombinant GPNMB treatment does not alter anabolic gene expression.</title>
<p>Anabolic gene expression was measured in DBA/2J GPNMB<sup>+</sup> and DBA/2J chondrocytes by RT-qPCR. Sox-9 mRNA was decreased with IL-1β treatment in DBA/2J GPNMB<sup>+</sup> (<bold>A</bold>) and DBA/2J (<bold>D</bold>) chondrocytes and was not rescued following treatment with recombinant GPNMB. Col2α1 expression was decreased with IL-1β treatment and was not increased significantly upon addition of recombinant GPNMB in DBA/2J GPNMB<sup>+</sup> (<bold>B</bold>) or DBA/2J (<bold>E</bold>) chondrocytes. Acan mRNA expression decreased with IL-1β treatment and was not rescued with the addition of recombinant GPNMB in DBA/2J GPNMB<sup>+</sup> (<bold>C</bold>) or DBA/2J (<bold>F</bold>) chondrocytes. Data presented as Mean ± SEM (n=6). ns= not significant, **= p&lt;0.01, ***=p&lt;0.001, ****=p&lt;0.0001.</p></caption>
<graphic xlink:href="658389v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Data from the DBA/2J chondrocytes (n=6) also showed no significant differences between untreated control cells and those treated with recombinant GPNMB alone (<xref rid="fig3" ref-type="fig">Figure 3D, E, F</xref>), while treatment with IL-1β alone significantly reduced expression of Sox-9, Col2α1 and ACAN (<xref rid="fig3" ref-type="fig">Figure 3D, E, F</xref>). The combination treatment of IL-1β and recombinant GPNMB also failed to rescue anabolic gene expression in DBA-2J chondrocytes (<xref rid="fig3" ref-type="fig">Figure 3D, E, F</xref>). These results confirm that IL-1β stimulation strongly inhibits anabolic gene expression and demonstrates that recombinant GPNMB treatment alone is not sufficient to rescue anabolic gene expression in DBA/2J GPNMB<sup>+</sup> or DBA/2J primary chondrocytes.</p>
</sec>
<sec id="s2i">
<title>DBA/2J mice display an accelerated progression of articular cartilage degeneration</title>
<p>The <italic>in vitro</italic> experiments demonstrated recombinant GPNMB treatment inhibited IL-1β-induced inflammation. To understand the possible role GPNMB may play in chondrocytes <italic>in vivo</italic>, we utilized a post-traumatic OA surgical mouse model, destabilization of the medial meniscus (DMM) (<xref ref-type="bibr" rid="c14">Culley et al., 2015</xref>; <xref ref-type="bibr" rid="c19">Glasson et al., 2007</xref>). First, we confirmed successful DMM surgery in C57BL/6J mice (n=7). Mice were subjected to DMM joint surgery to induce OA on the right joint and sham surgery on the left, which served as internal controls. The mice were sacrificed at 12-weeks post-surgery and joints were histologically analyzed via Toluidine Blue and Safranin O staining (<xref rid="fig4" ref-type="fig">Figure 4 A-B</xref>). The severity of the damage was analyzed following the Osteoarthritis Research Society International (OARSI) (<xref rid="fig4" ref-type="fig">Figure 4C</xref>) (<xref ref-type="bibr" rid="c43">Moskowitz, 2000</xref>; <xref ref-type="bibr" rid="c49">Pritzker et al., 2006</xref>). After 12 weeks, cartilage was intact in sham operated joints and in DMM operated joints fibrillation and erosion was visible in superficial and intermediate layers indicating our DMM surgery was successful.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4:</label>
<caption><title>DMM surgery resulted in cartilage fibrillation after 12 weeks in C57BL6/J mice and damage was accelerated in DBA/2J mice following DMM.</title>
<p>DMM surgery was validated in C57BL/6J mice. Cartilage was intact in sham operated joints (<bold>A</bold>) while DMM joints displayed superficial and intermediate cartilage damage (<bold>B</bold>) (tibia shown). (<bold>C</bold>) OARSI scores for sham and DMM operated joints. DBA/2J GPNMB<sup>+</sup> (<bold>D</bold>) and DBA/2J (<bold>E</bold>) mice, which lack functional GPNMB protein, were subjected to sham and DMM surgery and joints were stained with Toluidine blue. Black arrows indicate damaged areas. (<bold>F</bold>) OARSI scores for femur (MFC) and tibia (MTP) cartilage damage of DBA/2J GPNMB<sup>+</sup> and DBA/2J mice. Scale bar= 200µm in C57BL/6J joints and top panels and 100µm in magnified lower images (<bold>D, E</bold>). Images shown are representative and OARSI scorings from multiple images of n=7 each C57BL/6J, DBA/2J GPNMB<sup>+</sup> and DBA/2J mice. Data presented as Mean ± SEM (n=6). *p&lt;0.05, **= p&lt;0.01.</p></caption>
<graphic xlink:href="658389v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Next, DBA/2J GPNMB<sup>+</sup> and DBA/2J (n=7 each strain) mice were subjected to DMM surgery as described above. Cartilage damage caused by joint instability was observed in the articular cartilage of the medial compartment of the femur and tibia in both DBA/2J GPNMB<sup>+</sup> and DBA/2J mice (<xref rid="fig4" ref-type="fig">Figure 4D, E</xref>). Compared to DBA/2J GPNMB<sup>+</sup> control mice, the DBA/2J mutant mice demonstrated more severe cartilage damage (<xref rid="fig4" ref-type="fig">Figure 4D, E</xref>). The severity of the damage was analyzed following OARSI guidelines. DBA/2J GPNMB<sup>+</sup> mice showed max scores of 1.629 ± 0.2616 for the medial tibial plateau (MTP) and 0.7571 ± 0.1043 for the femoral medial condyle (MFC) (<xref rid="fig4" ref-type="fig">Figure 4F</xref>). The DBA/2J mice were significantly higher at 2.656 ± 0.355 for the medial tibial plateau and 1.473 ± 0.202 for the femoral medial condyle (<xref rid="fig4" ref-type="fig">Figure 4F</xref>). These results show the GPNMB mutant mice, which lack a fully functional GPNMB protein, displayed more severe cartilage damage upon DMM surgery compared to the controls.</p>
</sec>
<sec id="s2j">
<title>DBA/2J exhibit reduced ACAN and enhanced IL-6 expression compared to DBA/2J GPNMB<sup>+</sup></title>
<p>Given the severity of the cartilage damage seen in DBA/2J mice following DMM surgery, we next determined if ACAN expression was negatively affected in the mutant mice via immunohistochemistry. ACAN was chosen for analysis since it is the major cartilage proteoglycan responsible for bearing compressive loads during perambulation (<xref ref-type="bibr" rid="c53">Roughley, 2001</xref>; <xref ref-type="bibr" rid="c54">Roughley &amp; Mort, 2014</xref>). Sham operated joints showed intact cartilage and intact ACAN contents with no significant differences detected between the groups (<xref rid="fig5" ref-type="fig">Figure 5A, B</xref>). While the ACAN expression in DBA/2J GPNMB<sup>+</sup> DMM joints was also relatively high, DMM joint levels were much lower relative to sham operated controls and much higher than ACAN levels in the DBA/2J DMM mouse joints that showed severe cartilage damage (<xref rid="fig5" ref-type="fig">Figure 5A, B</xref>). We then quantified percent positive cells and found no significant differences in ACAN positive cells in sham operated joints between strains (<xref rid="fig5" ref-type="fig">Figure 5C</xref>), but a significant difference in ACAN production between DMM joints of DBA/2J GPNMB<sup>+</sup> and DBA/2J mice (<xref rid="fig5" ref-type="fig">Figure 5D</xref>). These results revealed that DBA/2J mice exhibited severe cartilage damage and that the damage is due, in part, to degradation of critical ECM components such as ACAN.</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5:</label>
<caption><title>ACAN expression is severely depleted, and IL-6 expression elevated following DMM in DBA/2J mice.</title>
<p>ACAN expression was not significantly altered in sham surgery mice (<bold>A-C</bold>) but was reduced following DMM in DBA/2J GPNMB<sup>+</sup> (<bold>A, D</bold>) and was severely depleted in DBA/2J (<bold>B, D</bold>) cartilage. Endogenous IL-6 expression is increased in DBA/2J animals without DMM (<bold>E-G</bold>). DBA/2J GPNMB<sup>+</sup> (<bold>E, H</bold>) and DBA/2J (<bold>B, H</bold>) cartilage showed an increase in IL-6 following DMM surgery. Scale bar= 200µm top panel and 100µm in magnified lower images. Images shown are representative and OARSI scores are taken multiple images of n=5-7 each DBA/2J GPNMB<sup>+</sup> and DBA/2J mice. Data presented as Mean ± SEM. *p&lt;0.05, **p&lt;0.01.</p></caption>
<graphic xlink:href="658389v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In addition to the anabolic marker ACAN, we also evaluated the expression of the inflammatory marker IL-6 following DMM surgery in both DBA/2J GPNMB<sup>+</sup> and DBA/2J mice (n=7 each strain). Sham and DMM joint sections were subjected to immunohistochemistry staining using an anti-IL-6 antibody. Both DBA/2J GPNMB<sup>+</sup> and DBA/2J mice expressed IL-6 as an inflammatory response to the post-traumatic joint damage caused by DMM (<xref rid="fig5" ref-type="fig">Figure 5E, F</xref>). Quantification of IL-6 expression showed significantly higher number of IL-6 positive cells in DBA/2J mice following sham surgery compared to DBA/2J GPNMB<sup>+</sup> controls (<xref rid="fig5" ref-type="fig">Figure 5G</xref>), suggesting DBA/2J mutant mice produce higher endogenous levels of proinflammatory IL-6 in the absence of functional GPNMB protein than control animals. This significance is further enhanced upon DMM surgery, where there is a significant increase in IL-6 positive cell numbers in the DBA/2J DMM joints compared to DBA/2J GPNMB<sup>+</sup> control DMM results (<xref rid="fig5" ref-type="fig">Figure 5H</xref>).</p>
</sec>
<sec id="s2k">
<title>GPNMB inhibits MAPK Kinase signaling in mouse primary chondrocytes</title>
<p>Previous literature has shown that GPNMB might play a role in the mitogen-activated protein kinase (MAPK) pathway in a variety of cell types such as mesenchymal stem cells, fibroblasts, and osteoclasts (<xref ref-type="bibr" rid="c4">Abdelmagid et al., 2015</xref>; <xref ref-type="bibr" rid="c17">Furochi et al., 2007</xref>; <xref ref-type="bibr" rid="c46">Ono et al., 2016</xref>). In this study we determined the effects of recombinant Gpnmb on MAPK singling in primary chondrocytes. Primary chondrocytes were isolated from C57BL/6J male mice (n=9), treated with recombinant GPNMB with or without IL-1β and terminated at 0, 10, 30 and 50 minutes after treatment. Protein lysates were probed for extracellular signal-related kinase (ERK), phospho-ERK (pERK), and GAPDH for loading control. Data showed the pERK was increased following IL-1β stimulation and decreased upon recombinant GPNMB treatment (<xref rid="fig6" ref-type="fig">Figure 6A, B</xref>). Recombinant GPNMB treatment inhibited pERK after 30 minutes. These results were semi-quantified by densitometry analyses (<xref rid="fig6" ref-type="fig">Figure 6C, D</xref>). These results indicate recombinant GPNMB plays a role in pERK inhibition following inflammation induced by IL-1β stimulation.</p>
<fig id="fig6" position="float" fig-type="figure">
<label>Figure 6:</label>
<caption><title>Recombinant GPNMB inhibits the MAPK signaling pathway in primary chondrocytes.</title>
<p>Immunoblotting of primary chondrocytes following IL-1β stimulation with and without recombinant GPNMB show GPNMB inhibits pERK at (<bold>A</bold>) 30 and (<bold>B</bold>) 50 minutes post-treatment. Densitometric analyses of pERK were done at (<bold>C</bold>) 30 and (<bold>D</bold>) 50 minutes. Experiments were repeated three times with similar results. Data presented as Mean ±SEM. ****=p&lt;0.0001, ns= not significant.</p></caption>
<graphic xlink:href="658389v1_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>While the role of GPNMB (osteoactivin) in fracture repair and bone regeneration is well characterized, nothing is known of its biological function in the joint or in chondrocytes, the principle cell type present in cartilage (<xref ref-type="bibr" rid="c5">Akkiraju &amp; Nohe, 2015</xref>; <xref ref-type="bibr" rid="c29">Hall, 2019</xref>). Furthermore, while GPNMB expression is increased under inflammatory conditions in human and porcine chondrocytes, it is unclear what role GPNMB plays in the pathogenesis of cartilage degenerative disorders such as OA (<xref ref-type="bibr" rid="c12">Conde et al., 2015</xref>; <xref ref-type="bibr" rid="c33">Jiang et al., 2011</xref>; <xref ref-type="bibr" rid="c47">Owen et al., 2003</xref>; <xref ref-type="bibr" rid="c56">Schlichting et al., 2014</xref>; <xref ref-type="bibr" rid="c66">Sun et al., 2015</xref>). OA is characterized by articular cartilage degeneration, abnormal bone formation (osteophytes) and chronic inflammation of the joint that results in pain and loss of mobility in affected individuals (<xref ref-type="bibr" rid="c20">Goldring et al., 2008</xref>; <xref ref-type="bibr" rid="c23">Goldring &amp; Otero, 2011</xref>; <xref ref-type="bibr" rid="c24">Goldring et al., 2011</xref>; <xref ref-type="bibr" rid="c26">Goldring &amp; Goldring, 2016</xref>; <xref ref-type="bibr" rid="c39">Loeser et al., 2016</xref>; <xref ref-type="bibr" rid="c40">Loeser et al., 2012</xref>). GPNMB has been shown to have anti-inflammatory effects in lymphocytes, macrophages, periodontal ligament cells and in microglia and astrocytes (<xref ref-type="bibr" rid="c10">Budge et al., 2020</xref>; <xref ref-type="bibr" rid="c36">Li et al., 2010</xref>; <xref ref-type="bibr" rid="c45">Neal et al., 2018</xref>; <xref ref-type="bibr" rid="c50">Ripoll et al., 2007</xref>; <xref ref-type="bibr" rid="c65">Song &amp; Lin, 2019</xref>; <xref ref-type="bibr" rid="c72">Zhou et al., 2017</xref>). Given these findings, we examined the biological role of GPNMB on inflammation and cartilage damage in primary chondrocytes <italic>in vitro</italic> and in articular cartilage <italic>in vivo</italic>. We provide the first evidence that GPNMB protects against cartilage damage in a post-traumatic mouse model and inhibits the expression of inflammatory cytokines and chemokines without altering anabolic gene expression in human and mouse primary chondrocytes.</p>
<p>In humans, GPNMB was increased in damaged high-grade osteoarthritic cartilage, primary chondrocytes, and cell lines <italic>in vitro</italic> and expression was increased with IL-1β proinflammatory stimulation. Additionally, treatment with recombinant GPNMB significantly reduced catabolic gene expression in primary human and mouse chondrocytes without altering anabolic gene expression, suggesting GPNMB does not affect chondrogenesis.</p>
<p>Expanding on our <italic>in vitro</italic> findings, we next determined the role of GPNMB <italic>in vivo</italic> via a DMM model of induced post-traumatic OA in mice (<xref ref-type="bibr" rid="c14">Culley et al., 2015</xref>; <xref ref-type="bibr" rid="c19">Glasson et al., 2007</xref>). Surgeries were performed on DBA/2J GPNMB<sup>+</sup> controls and in DBA/2J mice, which produce a non-functional truncated version of the GPNMB protein (<xref ref-type="bibr" rid="c3">Abdelmagid et al., 2014</xref>; <xref ref-type="bibr" rid="c11">Chung et al., 2007</xref>; <xref ref-type="bibr" rid="c28">Gutknecht et al., 2015</xref>). Inactive GPNMB leads to increased immune function and inflammation in these animals, with proinflammatory cytokine levels consistently higher than DBA/2J GPNMB<sup>+</sup> controls (<xref ref-type="bibr" rid="c15">Fan et al., 2010</xref>; <xref ref-type="bibr" rid="c68">Wilson et al., 2015</xref>; <xref ref-type="bibr" rid="c73">Zhou et al., 2009</xref>). When cartilage integrity was assessed post-surgery, DBA/2J mice displayed severe cartilage damage, suggesting GPNMB is beneficial for cartilage homeostasis.</p>
<p>To determine the signaling pathway responsible for the GPNMB-mediated reduction of inflammation in cartilage and primary chondrocytes, we evaluated the effects of GPNMB on the MAPK signaling pathway which is required for chondrocyte expression of Mmps, inflammatory cytokines, and Adamts in cartilage (<xref ref-type="bibr" rid="c13">Cui et al., 2020</xref>; <xref ref-type="bibr" rid="c21">Goldring, 1999</xref>; <xref ref-type="bibr" rid="c67">Tetsunaga et al., 2011</xref>). GPNMB is known to function via the ERK pathway in osteoclasts, motor-neuron-like cells, and fibroblasts (<xref ref-type="bibr" rid="c17">Furochi et al., 2007</xref>; <xref ref-type="bibr" rid="c46">Ono et al., 2016</xref>; <xref ref-type="bibr" rid="c64">Sondag et al., 2016</xref>). Also, ERK pathway activation has been shown to regulate osteoblast proliferation and differentiation (<xref ref-type="bibr" rid="c9">Bellido &amp; Plotkin, 2011</xref>; <xref ref-type="bibr" rid="c32">Jessop et al., 2002</xref>; <xref ref-type="bibr" rid="c69">Yan et al., 2012</xref>). However, in chondrocytes, activation of the ERK pathway has been shown to be detrimental resulting in chondrodysplasia and contributing to cartilage degradation in the pathogenesis of OA (<xref ref-type="bibr" rid="c6">Appleton, 2018</xref>; <xref ref-type="bibr" rid="c7">Appleton et al., 2010</xref>; <xref ref-type="bibr" rid="c37">Lin et al., 2021</xref>; <xref ref-type="bibr" rid="c70">Yang et al., 2008</xref>). Here, we are the first to show that the anti-inflammatory action of GPNMB in chondrocytes occurs via MAPK in primary chondrocytes with IL-1β-induced inflammation (<xref rid="fig7" ref-type="fig">Figure 7</xref>). Furthermore, our results suggest the strong anti-inflammatory function of GPNMB may be a result of concurrent inhibition of multiple catabolic markers (MMP-3, MMP-9, MMP-13, ADAMTS-4, and IL-6).</p>
<fig id="fig7" position="float" fig-type="figure">
<label>Figure 7:</label>
<caption><title>Schematic of the proposed mechanism of GPNMB anti-inflammatory function in chondrocytes.</title>
<p>(<bold>A</bold>) In healthy chondrocytes, GPNMB functions without inflammatory stimuli to modulate catabolic chemokines and cytokines and maintain cartilage homeostasis. (<bold>B</bold>) In the presence of inflammatory stimuli (IL-1β), GPNMB acts to modulate MAPK to reduce expression of catabolic chemokines and cytokines and reduce cartilage damage. (<bold>C</bold>) In DBA/2J mice with non-functional GPNMB, there is no inhibition of inflammatory molecules leading to increased catabolic expression and increased cartilage damage.</p></caption>
<graphic xlink:href="658389v1_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In conclusion, the data presented here demonstrates a novel anti-inflammatory role for GPNMB in cartilage and primary chondrocytes. While more work is needed to fully elucidate the mechanism <italic>in vitro</italic> and <italic>in vivo</italic>, these novel findings show GPNMB reduces catabolic gene expression and lays the foundation for future studies to assess the use of GPNMB as a possible alternative therapeutic agent in the treatment of OA.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>HTB-94 Cell Line Culture and Treatment Conditions</title>
<p>HTB-94 cells were cultured in DMEM/F12 (1:1, Cellgro Technologies, Lincoln, NE) culture medium supplemented with Penicillin/Streptomycin (Penicillin: 100 IU/ml, Sigma Aldrich, St. Louis, MO; Streptomycin: 100 µg/ml, Sigma Aldrich) and 10% fetal bovine serum (FBS, GE Healthcare, Chicago, IL) at 37°C and 5% CO<sub>2</sub>. Once established in culture, monolayer HTB-94 cells were rinsed with sterile PBS and serum-starved overnight prior to stimulation with 10 ng/ml of recombinant interleukin-1β (IL-1β; R&amp;D Systems, Niskayuna, NY) with or without recombinant GPNMB (R&amp;D Systems) in DMEM/F 12 (1:1) medium supplemented with Penicillin (100 IU/ml, Sigma-Aldrich), Streptomycin (100 μg/m, Sigma-Aldrich). HTB-94 experiments were set up in triplicate and results shown are from three separate experiments.</p>
</sec>
<sec id="s4b">
<title>Human Explant Culture and GPNMB/IL-1β Treatment</title>
<p>Explants were from undamaged regions of cartilage harvested from the discarded and de-identified patients (n=7). Undamaged cartilage regions were again identified using India Ink and then washed twice in sterile PBS. Cartilage explants (2 × 2 mm) were excised using a biopsy punch and maintained for 24 hours in supplemented DMEM/F12 culture medium as described above at 37°C and 5% CO<sub>2</sub>. After 24 hours, the medium was replaced with serum free DMEM overnight and then treated with 10 ng/ml IL-1β with or without recombinant 50 ng/ml GPNMB for 24 hours. Following pharmacological treatment, the explants were fixed in 4% paraformaldehyde (Sigma Aldrich) for 24 hours, decalcified using 14% Ethylenediaminetetraacetic acid (EDTA, Thermo Fisher Scientific, Waltham, MA), and processed. Explants were sectioned (5µm) and stained with Safranin-O stain (Thermo Fisher Scientific) (<xref ref-type="bibr" rid="c59">Schmitz et al., 2010</xref>).</p>
</sec>
<sec id="s4c">
<title>Mouse Strains</title>
<p>The following mouse strains were utilized in the completion of this study: C57BL/6J (wild type, WT, Stain #: 000664), DBA/2J (GPNMB mutant, Strain #: 000671), and DBA/2J GPNMB<sup>+</sup> (GPNMB control, Strain #: 007048). Mice were purchased from Jackson Laboratories and were housed at NEOMED in accordance with protocol guidelines approved by the NEOMED Institutional Animal Care and Use Committee (IACUC).</p>
</sec>
<sec id="s4d">
<title>Murine Primary Chondrocyte Isolation and Culture and Treatment Conditions</title>
<p>Primary articular chondrocytes isolated from hind limb dissections of 5-6-day-old mouse pups as previously described (<xref ref-type="bibr" rid="c27">Gosset et al., 2008</xref>; <xref ref-type="bibr" rid="c34">Jonason et al., 2015</xref>). In brief, skin and soft tissues were removed from the hindlimb bones and the femoral head, femoral condyle and tibial plateau cartilage were removed and placed in 1X sterile PBS on ice. Cartilage was washed twice with cold 1X sterile PBS and incubated twice (45 minutes per incubation) in a digestion solution consisting of Collagenase D (3 mg/ml, Sigma Aldrich) in serum free Dulbecco’s modified Eagle’s medium (DMEM) supplemented with Penicillin (100 IU/ml) and Streptomycin (µg/ml) at 37°C and 5% CO<sub>2</sub>. Then, cartilage digestion solution was diluted with serum free culture medium to a final concentration of 0.5 mg/ml and the cells were incubated overnight. After digestion, the cell solution was re-suspended and filtered using a sterile 40 µm cell strainer (Thermo Fisher Scientific). The filtered cell solution was centrifuged at 400g for 10 minutes, rinsed twice with sterile 1X PBS (centrifuging after each rinse), and re-suspended in culture medium consisting of DMEM supplemented with Penicillin (100 IU/ml), Streptomycin (100 μg/m) and 10% FBS. Mouse primary chondrocytes were counted via hemocytometer and seeded at high density in a 6-well culture dish for four days. Chondrocytes were serum stared overnight on day 5 and treated on day 6 with recombinant IL-1β (10 ng/ml) and recombinant GPNMB (50 ng/ml). On day 7, cells were harvested for immunoblotting and total RNA extraction.</p>
</sec>
<sec id="s4e">
<title>Cell Viability and Proliferation Assays</title>
<p>Cell viability in response to different doses of recombinant GPNMB was assessed using the MTT assay (Thermo Fisher Scientific). One day prior to treatment, primary chondrocytes were seeded into 96-well culture plates. Chondrocytes were treated for 72 hours with varying doses of recombinant GPNMB (R&amp;D systems) and the culture media was aspirated and 20 µl of MTT solution was added to the cells for 4 hours at 37°C and 5% CO<sub>2</sub>. Then, the supernatant was aspirated, dimethyl sulphoxide was added with gentle agitation for 15 minutes and absorbance was measured at 570 nm on an ELISA BioTek plate reader (BioTek, Winooski, VT). Cell viability assays were conducted 3 times (3 replicates per group) and treatment results were compared to untreated control cells.</p>
<p>Cellular proliferation of primary chondrocytes was determined with the CyQuant NF cell proliferation assay (Life Technologies, Carlsbad, CA). Mouse primary chondrocytes were harvested from 45-day-old pups and isolated as previously described. Cells were seeded in a 96-well culture plate for 24 hours and then treated with different concentrations of recombinant GPNMB for 72 hours. The media was then aspirated and replaced with 100 µl 1X binding solution and incubated for 1 hour at 37°C. Fluorescent intensity was measured on a BioTek plate reader (excitation at 485 nm and emission at 530 nm). Proliferation assays reported are the results of 3 separate experiments (3 replicates per group) and results of treated cells were compared to those of untreated control cells.</p>
</sec>
<sec id="s4f">
<title>RNA Isolation and RT-qPCR Analysis of Gene Expression</title>
<p>Total RNA was isolated from primary chondrocytes using Qiazol (Qiagen, Hilden, Germany) and purified using the RNeasy Mini Kit (Qiagen) following the manufacturer recommended protocols. RNA was quantified on a Nanodrop 2000 spectrophotometer (Nanodrop, Thermo Fisher Scientific). cDNA was synthesized from 1 µg total RNA using the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific).</p>
<p>RT-qPCR analyses were completed in triplicate using in-house designed primers (<xref rid="tbl1" ref-type="table">Table 1</xref>) and SYBR green PCR Master Mix (Thermo Fisher Scientific) on a Step One Plus Machine (Applied Biosystems, Waltham, MA). Expression of target genes was determined utilizing the delta-delta-Ct method and GAPDH was employed for normalization as an endogenous control (<xref ref-type="bibr" rid="c38">Livak &amp; Schmittgen, 2001</xref>; <xref ref-type="bibr" rid="c57">Schmittgen et al., 2008</xref>; <xref ref-type="bibr" rid="c58">Schmittgen &amp; Livak, 2008</xref>).</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><title>qPCR primers</title></caption>
<graphic xlink:href="658389v1_tbl1.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="658389v1_tbl1a.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec id="s4g">
<title>Immunoblotting</title>
<p>Total cellular protein was isolated from primary chondrocytes using radioimmunoprecipitation buffer (RIPA, Millipore, Burlington, MA) with added phosphatase inhibitor (Pierce, Rockford, IL). Protein concentrations were established using the Pierce BCA Protein Assay Kit (Pierce). Equivalent protein concentrations (20 µg) were loaded with 2X sample buffer (BioRad, Hercules, CA) into 12% SDS-PAGE gels. The Trans-Blot Turbo System (BioRad) was used to transfer proteins to a polyvinylidene fluoride membrane (PVDF, BioRad). Membranes were then blocked with 5% bovine serum albumin (BSA, Cytiva, Marlborough, MA) in 0.1% Tri-Buffered Saline with Tween 20 (TBST) for 1 hour at room temperature and then incubated as described at 4°C overnight with primary antibodies listed in <xref rid="tbl2" ref-type="table">Table 2</xref>. Membranes were rinsed twice in TBST (5 minutes per wash) with gentle shaking and a Horseradish peroxidase (HRP)-linked secondary in TBST (Cell Signaling Technologies, Danver, MA) was applied to the membranes for 1 hour. Immunoblots were developed with chemiluminescent substrate (Pierce). Bands images and intensity were determined using a Pxi imaging system and Syngene software (Syngene, Bangalore, India).</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2:</label>
<caption><title>Table of Primary Antibodies</title></caption>
<graphic xlink:href="658389v1_tbl2.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec id="s4h">
<title>DMM Surgery</title>
<p>DMM was performed in 12-week-old male DBA/2J GPNMB<sup>+</sup> (control, n=7) and DBA/2J (mutant, n=7) mice to induce OA. DMM was performed as previously described and surgical procedures were approved by the NEOMED IACUC committee (<xref ref-type="bibr" rid="c14">Culley et al., 2015</xref>; <xref ref-type="bibr" rid="c19">Glasson et al., 2007</xref>). Only male mice were studied at this time. Although recent literature has shown that female mice do in fact develop post traumatic-OA, due to the preliminary nature of this study and resource constrains, only male mice were studied at this time (<xref ref-type="bibr" rid="c30">Hwang et al., 2021</xref>; <xref ref-type="bibr" rid="c41">Ma et al., 2007</xref>). Female mice will be included in future studies. The right knee joint was subjected to microsurgery under a sterilized microscope. The medial menisci tibial ligament (MMTL), which anchors the medial meniscus (MM) to the tibial plateau, was transected to destabilize the joint. The left knee joint was subjected to sham surgery as a control. The knee was surgically opened but the MMTL was not transected. Mice were sacrificed 12-weeks post-surgery.</p>
</sec>
<sec id="s4i">
<title>DMM Tissue Isolation</title>
<p>The sham and DMM surgery mouse knee joints were harvested as previously described (<xref ref-type="bibr" rid="c14">Culley et al., 2015</xref>). Soft tissues were removed and the joints were fixed for 24 hours in 4% paraformaldehyde with gentle agitation. The fixed joints were rinsed for 1 hour in PBS and then decalcified for 10 days in 14% EDTA. The buffer was changed three times per week during the decalcification process. Decalcified joints were washed for 6 hours in PBS, processed, and embedded in paraffin and cut into 6 µm sections.</p>
</sec>
<sec id="s4j">
<title>Histological Assessment of Mouse Sham and DMM Knee Joints</title>
<p>To assess cartilage damage in the sham and DMM surgery mouse joints, the sections were stained with Toluidine blue/fast green stain. Three sections were selected at 90 µm intervals for histological evaluation following the Osteoarthritis Research Society International (OARSI) scoring system (<xref ref-type="bibr" rid="c49">Pritzker et al., 2006</xref>). Results were presented as ± mean of the maximum joint score.</p>
</sec>
<sec id="s4k">
<title>Immunohistochemistry</title>
<p>Histological sections of sham and DMM mouse knee joints were subjected to immunohistochemical analysis to measure expression of catabolic and anabolic proteins in damaged and undamaged regions of the cartilage. Histological sections were de-paraffinized for 1 hour and cleared in xylene (Thermo Fisher Scientific) before they were rehydrated in a graded ethanol series. For antigen retrieval, the sections were treated with 0.01 M citrate buffer at 60°C overnight in a water bath. Activity of endogenous peroxidase was quenched using 3% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) solution for 15 minutes before blocking with 5% BSA for 1 hour. Sections were then treated overnight at 4°C with primary rabbit anti-Mmp-13 (Abcam, Cambridge, England), rabbit anti-Il-6 (Abcam), rabbit anti-Gpnmb (LSBio, Lynnwood, WA) or rabbit anti-Acan (Bioss, Woburn, MA). Biotinylated goat anti-rabbit secondary antibody (Vector Laboratories, Newark, CA) was added for 1 hour and the Vectastain Elite ABC HRP kit was sued with 3, 3’-Diaminobenzidine (DAB, Vector Laboratories) was used for signal development. The sections were imaged using a BX61VS microscope (Olympus Life Science, Center Valley, PA) and positive cells were quantified with ImageJ software (<xref ref-type="bibr" rid="c60">Schneider et al., 2012</xref>).</p>
</sec>
<sec id="s4l">
<title>Statistical Analyses</title>
<p>For all data generated, differences between individual groups were analyzed using GraphPad Prism software (GraphPad, La Jolla, CA). All cell culture experiments were repeated a minimum of three times with similar results. DMM experiments were repeated twice with 6 individuals included in each trial. In comparisons of multiple groups, One-way analysis of variance (ANOVA) tests were employed followed with Tukey’s post hoc tests. Comparisons of two groups employed unpaired <italic>T</italic>-tests. For histological scoring, MannWhitney and KruskalWallis tests were performed with Dunn’s post hoc analyses were conducted as the nonparametric equivalents for the independent samples t-test and One-way ANOVA. Differences were considered significant where p&lt;0.05 and graphs depict group means + standard error of the average (±SEM).</p>
</sec>
</sec>
</body>
<back>
<sec id="s7">
<title>Suppmentary Figures</title>
<fig id="figS1" position="float" fig-type="figure">
<label>Supplemental figure 1:</label>
<caption><title>The structure of full length, recombinant and mutant GPNMB proteins.</title>
<p>The full length GPNMB is 574 amino acids and has several domains including a N-terminal extracellular domain signal peptide (SS, 1-22), an arginine-glycine-aspartic acid (RGD), a polycystic kidney disease (PKD), and a proline rich repeat (PRRD) domain. The transmembrane domain (TM) of GPNMB is 20 amino acids (503-523). The C-terminal intracellular domain holds an ITAM motif and Di-leucine signal. The recombinant form of GPNMB represents the N-terminal portion of the molecule (23-502) and is derived from a mouse myeloma cell line. The DBA/2J mutant GPNMB is a truncated version of the protein (1-150).</p></caption>
<graphic xlink:href="658389v1_figS1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS2" position="float" fig-type="figure">
<label>Supplemental figure 2:</label>
<caption><title>Endogenous levels of catabolic genes are not significantly different between DBA/2J GPNMB<sup>+</sup> and DBA/2J primary chondrocytes.</title>
<p>RT-qPCR analyses of (<bold>A</bold>) Mmp-3, (<bold>B</bold>) Mmp-9, (<bold>C</bold>) Mmp-13, (<bold>D</bold>) Adamts-4 and (<bold>E</bold>) Il-6 expression detected no significant differences in endogenous mRNA expression prior to treatment. Experiments were repeated three times in triplicate with similar results. Data presented as Mean ± SEM; ns = not significant.</p></caption>
<graphic xlink:href="658389v1_figS2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figS3" position="float" fig-type="figure">
<label>Supplemental figure 3:</label>
<caption><title>Endogenous levels of anabolic genes are not significantly different between DBA/2J GPNMB<sup>+</sup> (control) and DBA/2J primary chondrocytes.</title>
<p>RT-qPCR analyses of endogenous anabolic gene expression found no significant differences in (<bold>A</bold>) Sox-9, (<bold>B</bold>) Type-II collagen (Col2α1) or (C) ACAN expression. Experiments were repeated three times in triplicate with similar results. Data presented as Mean ± SEM; ns = not significant.</p></caption>
<graphic xlink:href="658389v1_figS3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<ack>
<title>Acknowledgements</title>
<p>Research was funded by a generous gift from the Cook Family Fund for Orthopaedic Research and the Graduate School of Kent State University.</p>
</ack>
<sec id="d1e1684" sec-type="additional-information">
<title>Additional information</title>
<sec id="s6" sec-type="data-availability">
<title>Data and Materials Availability</title>
<p>All data supporting the findings of this study are available within the article and its Supplementary Information Files and from the corresponding author on reasonable request.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdelmagid</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Barbe</surname>, <given-names>M. F.</given-names></string-name>, <string-name><surname>Hadjiargyrou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Owen</surname>, <given-names>T. A.</given-names></string-name>, <string-name><surname>Razmpour</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Rehman</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Popoff</surname>, <given-names>S. N.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2010</year>). <article-title>Temporal and spatial expression of osteoactivin during fracture repair</article-title>. <source>Journal of Cellular Biochemistry</source>, <volume>111</volume>(<issue>2</issue>), <fpage>295</fpage>–<lpage>309</lpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdelmagid</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Barbe</surname>, <given-names>M. F.</given-names></string-name>, <string-name><surname>Rico</surname>, <given-names>M. C.</given-names></string-name>, <string-name><surname>Salihoglu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Arango-Hisijara</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Selim</surname>, <given-names>A. H.</given-names></string-name>, <string-name><surname>Anderson</surname>, <given-names>M. G.</given-names></string-name>, <string-name><surname>Owen</surname>, <given-names>T. A.</given-names></string-name>, <string-name><surname>Popoff</surname>, <given-names>S. N.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function</article-title>. <source>Experimental cell research</source>, <volume>314</volume>(<issue>13</issue>), <fpage>2334</fpage>–<lpage>2351</lpage>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdelmagid</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Belcher</surname>, <given-names>J. Y.</given-names></string-name>, <string-name><surname>Moussa</surname>, <given-names>F. M.</given-names></string-name>, <string-name><surname>Lababidi</surname>, <given-names>S. L.</given-names></string-name>, <string-name><surname>Sondag</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Novak</surname>, <given-names>K. M.</given-names></string-name>, <string-name><surname>Sanyurah</surname>, <given-names>A. S.</given-names></string-name>, <string-name><surname>Frara</surname>, <given-names>N. A.</given-names></string-name>, <string-name><surname>Razmpour</surname>, <given-names>R.</given-names></string-name>, &amp; <string-name><surname>Del Carpio-Cano</surname>, <given-names>F. E.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro</article-title>. <source>The American journal of pathology</source>, <volume>184</volume>(<issue>3</issue>), <fpage>697</fpage>–<lpage>713</lpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abdelmagid</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Sondag</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Moussa</surname>, <given-names>F. M.</given-names></string-name>, <string-name><surname>Belcher</surname>, <given-names>J. Y.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Stinnett</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Novak</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mbimba</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Khol</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hankenson</surname>, <given-names>K. D.</given-names></string-name>, <string-name><surname>Malcuit</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Mutation in Osteoactivin Promotes Receptor Activator of NFkappaB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function</article-title>. <source>J Biol Chem</source>, <volume>290</volume>(<issue>33</issue>), <fpage>20128</fpage>–<lpage>20146</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.624270</pub-id></mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akkiraju</surname>, <given-names>H.</given-names></string-name>, &amp; <string-name><surname>Nohe</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Role of chondrocytes in cartilage formation, progression of osteoarthritis and cartilage regeneration</article-title>. <source>Journal of developmental biology</source>, <volume>3</volume>(<issue>4</issue>), <fpage>177</fpage>–<lpage>192</lpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Appleton</surname>, <given-names>C. T.</given-names></string-name></person-group> (<year>2018</year>). <article-title>Osteoarthritis year in review 2017: biology</article-title>. <source>Osteoarthritis Cartilage</source>, <volume>26</volume>(<issue>3</issue>), <fpage>296</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2017.10.008</pub-id></mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Appleton</surname>, <given-names>C. T. G.</given-names></string-name>, <string-name><surname>Usmani</surname>, <given-names>S. E.</given-names></string-name>, <string-name><surname>Mort</surname>, <given-names>J. S.</given-names></string-name>, &amp; <string-name><surname>Beier</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2010</year>). <article-title>Rho/ROCK and MEK/ERK activation by transforming growth factor-α induces articular cartilage degradation</article-title>. <source>Laboratory Investigation</source>, <volume>90</volume>(<issue>1</issue>), <fpage>20</fpage>–<lpage>30</lpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arosarena</surname>, <given-names>O. A.</given-names></string-name>, <string-name><surname>Barr</surname>, <given-names>E. W.</given-names></string-name>, <string-name><surname>Thorpe</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Yankey</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Tarr</surname>, <given-names>J. T.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2018</year>). <article-title>Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases</article-title>. <source>Journal of Cellular Physiology</source>, <volume>233</volume>(<issue>1</issue>), <fpage>409</fpage>–<lpage>421</lpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bellido</surname>, <given-names>T.</given-names></string-name>, &amp; <string-name><surname>Plotkin</surname>, <given-names>L. I.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability</article-title>. <source>Bone</source>, <volume>49</volume>(<issue>1</issue>), <fpage>50</fpage>–<lpage>55</lpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Budge</surname>, <given-names>K. M.</given-names></string-name>, <string-name><surname>Neal</surname>, <given-names>M. L.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>J. R.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Transgenic overexpression of GPNMB protects against MPTP-induced neurodegeneration</article-title>. <source>Molecular Neurobiology</source>, <volume>57</volume>(<issue>7</issue>), <fpage>2920</fpage>–<lpage>2933</lpage>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chung</surname>, <given-names>J.-S.</given-names></string-name>, <string-name><surname>Sato</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Dougherty</surname>, <given-names>I. I.</given-names></string-name>, <string-name><surname>Cruz Jr</surname>, <given-names>P. D.</given-names></string-name>, &amp; <string-name><surname>Ariizumi</surname>, <given-names>K.</given-names></string-name></person-group> (<year>2007</year>). <article-title>DC-HIL is a negative regulator of T lymphocyte activation</article-title>. <source>Blood</source>, <volume>109</volume>(<issue>10</issue>), <fpage>4320</fpage>–<lpage>4327</lpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conde</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Scotece</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Abella</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Gómez</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>López</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Villar</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hermida</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Pino</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gómez-Reino</surname>, <given-names>J. J.</given-names></string-name>, &amp; <string-name><surname>Gualillo</surname>, <given-names>O.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Identification of novel adipokines in the joint. Differential expression in healthy and osteoarthritis tissues</article-title>. <source>PLoS ONE</source>, <volume>10</volume>(<issue>4</issue>), <fpage>e0123601</fpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zhong</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Y.</given-names></string-name>, &amp; <string-name><surname>Lu</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies</article-title>. <source>EClinicalMedicine</source>, <volume>29</volume>, <fpage>100587</fpage>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Culley</surname>, <given-names>K. L.</given-names></string-name>, <string-name><surname>Dragomir</surname>, <given-names>C. L.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wondimu</surname>, <given-names>E. B.</given-names></string-name>, <string-name><surname>Coico</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Plumb</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Otero</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Mouse models of osteoarthritis: surgical model of posttraumatic osteoarthritis induced by destabilization of the medial meniscus</article-title>. <source>Methods Mol Biol</source>, <volume>1226</volume>, <fpage>143</fpage>–<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-1619-1_12</pub-id></mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Mo</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kaplan</surname>, <given-names>H.</given-names></string-name>, &amp; <string-name><surname>Cooper</surname>, <given-names>N.</given-names></string-name></person-group> (<year>2010</year>). <article-title>Early involvement of immune/inflammatory response genes in retinal degeneration in DBA/2J mice</article-title>. <source>Ophthalmology and eye diseases</source>, <volume>2</volume>, <fpage>117917211000200005</fpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frara</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Abdelmagid</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Sondag</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Moussa</surname>, <given-names>F. M.</given-names></string-name>, <string-name><surname>Yingling</surname>, <given-names>V. R.</given-names></string-name>, <string-name><surname>Owen</surname>, <given-names>T. A.</given-names></string-name>, <string-name><surname>Popoff</surname>, <given-names>S. N.</given-names></string-name>, <string-name><surname>Barbe</surname>, <given-names>M. F.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Transgenic expression of osteoactivin/gpnmb enhances bone formation in vivo and osteoprogenitor differentiation ex vivo</article-title>. <source>Journal of cellular physiology</source>, <volume>231</volume>(<issue>1</issue>), <fpage>72</fpage>–<lpage>83</lpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Furochi</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Tamura</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Mameoka</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Yamada</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Ogawa</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Hirasaka</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Okumura</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Imagawa</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Oguri</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name><surname>Ishidoh</surname>, <given-names>K.</given-names></string-name></person-group> (<year>2007</year>). <article-title>Osteoactivin fragments produced by ectodomain shedding induce MMP-3 expression via ERK pathway in mouse NIH-3T3 fibroblasts</article-title>. <source>FEBS letters</source>, <volume>581</volume>(<issue>30</issue>), <fpage>5743</fpage>–<lpage>5750</lpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Gauci</surname>, <given-names>S. J.</given-names></string-name>, <string-name><surname>Stanton</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Little</surname>, <given-names>C. B.</given-names></string-name>, &amp; <string-name><surname>Fosang</surname>, <given-names>A. J.</given-names></string-name></person-group> (<year>2017</year>). <chapter-title>Proteoglycan and collagen degradation in osteoarthritis</chapter-title>. <person-group person-group-type="editor"><string-name><surname>Grässel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Aszódi</surname>, <given-names>A.</given-names></string-name></person-group> <source>Cartilage: Volume 2: Pathophysiology</source>, <publisher-name>Springer</publisher-name> <fpage>41</fpage>–<lpage>61</lpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Glasson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Blanchet</surname>, <given-names>T.</given-names></string-name>, &amp; <string-name><surname>Morris</surname>, <given-names>E.</given-names></string-name></person-group> (<year>2007</year>). <article-title>The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse</article-title>. <source>Osteoarthritis and Cartilage</source>, <volume>15</volume>(<issue>9</issue>), <fpage>1061</fpage>–<lpage>1069</lpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldring</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Otero</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Tsuchimochi</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Ijiri</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism</article-title>. <source>Annals of the Rheumatic Diseases</source>, <volume>67</volume>(<issue>Suppl 3</issue>), <fpage>iii75</fpage>–<lpage>iii82</lpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name></person-group> (<year>1999</year>). <article-title>The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models</article-title>. <source>Connective Tissue Research</source>, <volume>40</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name></person-group> (<year>2012</year>). <article-title>Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis</article-title>. <source>Therapeutic advances in musculoskeletal disease</source>, <volume>4</volume>(<issue>4</issue>), <fpage>269</fpage>–<lpage>285</lpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name>, &amp; <string-name><surname>Otero</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Inflammation in osteoarthritis</article-title>. <source>Current opinion in rheumatology</source>, <volume>23</volume>(<issue>5</issue>), <fpage>471</fpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name>, <string-name><surname>Otero</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Plumb</surname>, <given-names>D. A.</given-names></string-name>, <string-name><surname>Dragomir</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Favero</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>El Hachem</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hashimoto</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Roach</surname>, <given-names>H. I.</given-names></string-name>, <string-name><surname>Olivotto</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Borzi</surname>, <given-names>R. M.</given-names></string-name>, &amp; <string-name><surname>Marcu</surname>, <given-names>K. B.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Roles of Inflammatory and Anabolic Cytokines in Cartilage Metabolism: Signals and Multiple Effectors Converge Upon Mmp-13 Regulation in Osteoarthritis</article-title>. <source>European Cells &amp; Materials</source>, <volume>21</volume>, <fpage>202</fpage>–<lpage>220</lpage>. <pub-id pub-id-type="doi">10.22203/eCM.v021a16</pub-id></mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldring</surname>, <given-names>S. R.</given-names></string-name>, &amp; <string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name></person-group> (<year>2004</year>). <article-title>The role of cytokines in cartilage matrix degeneration in osteoarthritis</article-title>. <source>Clinical Orthopaedics and Related Research®</source>, <volume>427</volume>, <fpage>S27</fpage>–<lpage>S36</lpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldring</surname>, <given-names>S. R.</given-names></string-name>, &amp; <string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage–bone crosstalk</article-title>. <source>Nature Reviews Rheumatology</source>, <volume>12</volume>(<issue>11</issue>), <fpage>632</fpage>–<lpage>644</lpage>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gosset</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Berenbaum</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Thirion</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name><surname>Jacques</surname>, <given-names>C.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Primary culture and phenotyping of murine chondrocytes</article-title>. <source>Nature Protocols</source>, <volume>3</volume>(<issue>8</issue>), <fpage>1253</fpage>–<lpage>1260</lpage>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gutknecht</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Geiger</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Joas</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Dörfel</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Salih</surname>, <given-names>H. R.</given-names></string-name>, <string-name><surname>Müller</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Grünebach</surname>, <given-names>F.</given-names></string-name>, &amp; <string-name><surname>Rittig</surname>, <given-names>S. M.</given-names></string-name></person-group> (<year>2015</year>). <article-title>The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells</article-title>. <source>Cell Communication and Signaling</source>, <volume>13</volume>, <fpage>1</fpage>–<lpage>15</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname>, <given-names>A. C.</given-names></string-name></person-group> (<year>2019</year>). <article-title>The role of chondrocyte morphology and volume in controlling phenotype— implications for osteoarthritis, cartilage repair, and cartilage engineering</article-title>. <source>Current Rheumatology Reports</source>, <volume>21</volume>, <fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hwang</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Hong</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Kim</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2021</year>). <article-title>Comparison of joint degeneration and pain in male and female mice in DMM model of osteoarthritis</article-title>. <source>Osteoarthritis and Cartilage</source>, <volume>29</volume>(<issue>5</issue>), <fpage>728</fpage>–<lpage>738</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Järve</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mühlstedt</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Qadri</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Nickl</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Schulz</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Hübner</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Özcelik</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name><surname>Bader</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2017</year>). <article-title>Adverse left ventricular remodeling by glycoprotein nonmetastatic melanoma protein B in myocardial infarction</article-title>. <source>The FASEB Journal</source>, <volume>31</volume>(<issue>2</issue>), <fpage>556</fpage>–<lpage>568</lpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jessop</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Rawlinson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Pitsillides</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Lanyon</surname>, <given-names>L.</given-names></string-name></person-group> (<year>2002</year>). <article-title>Mechanical strain and fluid movement both activate extracellular regulated kinase (ERK) in osteoblast-like cells but via different signaling pathways</article-title>. <source>Bone</source>, <volume>31</volume>(<issue>1</issue>), <fpage>186</fpage>–<lpage>194</lpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname>, <given-names>S. S.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>C.-H.</given-names></string-name>, <string-name><surname>Tseng</surname>, <given-names>K.-Y.</given-names></string-name>, <string-name><surname>Tsai</surname>, <given-names>F.-Y.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>M. J.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>I.-S.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>J.-L.</given-names></string-name>, &amp; <string-name><surname>Lin</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Gene expression profiling suggests a pathological role of human bone marrow-derived mesenchymal stem cells in aging-related skeletal diseases</article-title>. <source>Aging (Albany NY)</source>, <volume>3</volume>(<issue>7</issue>), <fpage>672</fpage>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Jonason</surname>, <given-names>J. H.</given-names></string-name>, <string-name><surname>Hoak</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>O’keefe</surname>, <given-names>R. J.</given-names></string-name></person-group> (<year>2015</year>). <chapter-title>Primary murine growth plate and articular chondrocyte isolation and cell culture</chapter-title>. In <person-group person-group-type="editor"><string-name><surname>Westendorf</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>van Wijnen</surname>, <given-names>A. J.</given-names></string-name></person-group> <source>Osteoporosis and Osteoarthritis</source> (pp. <fpage>11</fpage>–<lpage>18</lpage>). <publisher-name>Springer</publisher-name>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kawahara</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hirata</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ohbuchi</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Nishi</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Maeda</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kuniyasu</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Yamada</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Maeda</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Tsuji</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Sawada</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2016</year>). <article-title>The novel monoclonal antibody 9F5 reveals expression of a fragment of GPNMB/osteoactivin processed by furin-like protease (s) in a subpopulation of microglia in neonatal rat brain</article-title>. <source>Glia</source>, <volume>64</volume>(<issue>11</issue>), <fpage>1938</fpage>–<lpage>1961</lpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Castano</surname>, <given-names>A. P.</given-names></string-name>, <string-name><surname>Hudson</surname>, <given-names>T. E.</given-names></string-name>, <string-name><surname>Nowlin</surname>, <given-names>B. T.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>S.-L.</given-names></string-name>, <string-name><surname>Bonventre</surname>, <given-names>J. V.</given-names></string-name>, <string-name><surname>Swanson</surname>, <given-names>K. D.</given-names></string-name>, &amp; <string-name><surname>Duffield</surname>, <given-names>J. S.</given-names></string-name></person-group> (<year>2010</year>). <article-title>The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair</article-title>. <source>The FASEB Journal</source>, <volume>24</volume>(<issue>12</issue>), <fpage>4767</fpage>–<lpage>4781</lpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Miao</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>X.</given-names></string-name>, &amp; <string-name><surname>Bai</surname>, <given-names>L.</given-names></string-name></person-group> (<year>2021</year>). <article-title>JUNB-FBXO21-ERK axis promotes cartilage degeneration in osteoarthritis by inhibiting autophagy</article-title>. <source>Aging Cell</source>, <volume>20</volume>(<issue>2</issue>), <fpage>e13306</fpage>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Livak</surname>, <given-names>K. J.</given-names></string-name>, &amp; <string-name><surname>Schmittgen</surname>, <given-names>T. D.</given-names></string-name></person-group> (<year>2001</year>). <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔCT method</article-title>. <source>Methods</source>, <volume>25</volume>(<issue>4</issue>), <fpage>402</fpage>–<lpage>408</lpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loeser</surname>, <given-names>R. F.</given-names></string-name>, <string-name><surname>Collins</surname>, <given-names>J. A.</given-names></string-name>, &amp; <string-name><surname>Diekman</surname>, <given-names>B. O.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Ageing and the pathogenesis of osteoarthritis</article-title>. <source>Nature Reviews Rheumatology</source>, <volume>12</volume>(<issue>7</issue>), <fpage>412</fpage>–<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2016.65</pub-id></mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Loeser</surname>, <given-names>R. F.</given-names></string-name>, <string-name><surname>Goldring</surname>, <given-names>S. R.</given-names></string-name>, <string-name><surname>Scanzello</surname>, <given-names>C. R.</given-names></string-name>, &amp; <string-name><surname>Goldring</surname>, <given-names>M. B.</given-names></string-name></person-group> (<year>2012</year>). <article-title>Osteoarthritis: A disease of the joint as an organ</article-title>. <source>Arthritis and Rheumatism</source>, <volume>64</volume>(<issue>6</issue>), <fpage>1697</fpage>–<lpage>1707</lpage>. <pub-id pub-id-type="doi">10.1002/art.34453</pub-id></mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname>, <given-names>H.-L.</given-names></string-name>, <string-name><surname>Blanchet</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Peluso</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Hopkins</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Morris</surname>, <given-names>E.</given-names></string-name>, &amp; <string-name><surname>Glasson</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2007</year>). <article-title>Osteoarthritis severity is sex dependent in a surgical mouse model</article-title>. <source>Osteoarthritis and Cartilage</source>, <volume>15</volume>(<issue>6</issue>), <fpage>695</fpage>–<lpage>700</lpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mengshol</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Vincenti</surname>, <given-names>M. P.</given-names></string-name>, &amp; <string-name><surname>Brinckerhoff</surname>, <given-names>C. E.</given-names></string-name></person-group> (<year>2001</year>). <article-title>IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways</article-title>. <source>Nucleic acids research</source>, <volume>29</volume>(<issue>21</issue>), <fpage>4361</fpage>–<lpage>4372</lpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moskowitz</surname>, <given-names>R. W.</given-names></string-name></person-group> (<year>2000</year>). <article-title>Role of collagen hydrolysate in bone and joint disease</article-title>. <source>Seminars in arthritis and rheumatism</source> <volume>30</volume>: <fpage>87</fpage>–<lpage>99</lpage></mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murata</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Yoshino</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Tsuruma</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Moriguchi</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Oyagi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tanaka</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ishisaka</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shimazawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fukunaga</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Hara</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2015</year>). <article-title>The extracellular fragment of GPNMB (Glycoprotein nonmelanosoma protein B, osteoactivin) improves memory and increases hippocampal GluA1 levels in mice</article-title>. <source>Journal of Neurochemistry</source>, <volume>132</volume>(<issue>5</issue>), <fpage>583</fpage>–<lpage>594</lpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neal</surname>, <given-names>M. L.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>A. M.</given-names></string-name>, <string-name><surname>Budge</surname>, <given-names>K. M.</given-names></string-name>, <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name>, &amp; <string-name><surname>Richardson</surname>, <given-names>J. R.</given-names></string-name></person-group> (<year>2018</year>). <article-title>The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor</article-title>. <source>Journal of neuroinflammation</source>, <volume>15</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ono</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Tsuruma</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Takata</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shimazawa</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Hara</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na+/K+-ATPase</article-title>. <source>Scientific Reports</source>, <volume>6</volume>(<issue>1</issue>), <fpage>23241</fpage>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Owen</surname>, <given-names>T. A.</given-names></string-name>, <string-name><surname>Smock</surname>, <given-names>S. L.</given-names></string-name>, <string-name><surname>Prakash</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Pinder</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Brees</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Krull</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Castleberry</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Clancy</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Marks</surname> <suffix>Jr</suffix>, <given-names>S.</given-names></string-name> C., &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2003</year>). <article-title>Identification and characterization of the genes encoding human and mouse osteoactivin</article-title>. <source>Critical Reviews™ in Eukaryotic Gene Expression</source>, <volume>13</volume>(<issue>2-4</issue>).</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oyewumi</surname>, <given-names>M. O.</given-names></string-name>, <string-name><surname>Manickavasagam</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Novak</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wehrung</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Paulic</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Moussa</surname>, <given-names>F. M.</given-names></string-name>, <string-name><surname>Sondag</surname>, <given-names>G. R.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells</article-title>. <source>Oncotarget</source>, <volume>7</volume>(<issue>12</issue>), <fpage>13932</fpage>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pritzker</surname>, <given-names>K. P.</given-names></string-name>, <string-name><surname>Gay</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Jimenez</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ostergaard</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Pelletier</surname>, <given-names>J.-P.</given-names></string-name>, <string-name><surname>Revell</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Salter</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>Van den Berg</surname>, <given-names>W.</given-names></string-name></person-group> (<year>2006</year>). <article-title>Osteoarthritis cartilage histopathology: grading and staging</article-title>. <source>Osteoarthritis and Cartilage</source>, <volume>14</volume>(<issue>1</issue>), <fpage>13</fpage>–<lpage>29</lpage>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ripoll</surname>, <given-names>V. M.</given-names></string-name>, <string-name><surname>Irvine</surname>, <given-names>K. M.</given-names></string-name>, <string-name><surname>Ravasi</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Sweet</surname>, <given-names>M. J.</given-names></string-name>, &amp; <string-name><surname>Hume</surname>, <given-names>D. A.</given-names></string-name></person-group> (<year>2007</year>). <article-title>Gpnmb is induced in macrophages by IFN-γ and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses</article-title>. <source>The Journal of Immunology</source>, <volume>178</volume>(<issue>10</issue>), <fpage>6557</fpage>–<lpage>6566</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robinson</surname>, <given-names>W. H.</given-names></string-name>, <string-name><surname>Lepus</surname>, <given-names>C. M.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Raghu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Mao</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Lindstrom</surname>, <given-names>T. M.</given-names></string-name>, &amp; <string-name><surname>Sokolove</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis</article-title>. <source>Nature Reviews Rheumatology</source>, <volume>12</volume>(<issue>10</issue>), <fpage>580</fpage>–<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2016.136</pub-id></mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rose</surname>, <given-names>A. A.</given-names></string-name>, <string-name><surname>Annis</surname>, <given-names>M. G.</given-names></string-name>, <string-name><surname>Dong</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Pepin</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Hallett</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Siegel</surname>, <given-names>P. M.</given-names></string-name></person-group> (<year>2010</year>). <article-title>ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties</article-title>. <source>PLoS ONE</source>, <volume>5</volume>(<issue>8</issue>), <fpage>e12093</fpage>.</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roughley</surname>, <given-names>P. J.</given-names></string-name></person-group> (<year>2001</year>). <article-title>Articular cartilage and changes in arthritis: noncollagenous proteins and proteoglycans in the extracellular matrix of cartilage</article-title>. <source>Arthritis Research &amp; Therapy</source>, <volume>3</volume>(<issue>6</issue>), <fpage>1</fpage>–<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roughley</surname>, <given-names>P. J.</given-names></string-name>, &amp; <string-name><surname>Mort</surname>, <given-names>J. S.</given-names></string-name></person-group> (<year>2014</year>). <article-title>The role of aggrecan in normal and osteoarthritic cartilage</article-title>. <source>Journal of Experimental Orthopaedics</source>, <volume>1</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Smock</surname>, <given-names>S. L.</given-names></string-name>, <string-name><surname>Rico</surname>, <given-names>M. C.</given-names></string-name>, <string-name><surname>Owen</surname>, <given-names>T. A.</given-names></string-name>, &amp; <string-name><surname>Popoff</surname>, <given-names>S. N.</given-names></string-name></person-group> (<year>2002</year>). <article-title>Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts</article-title>. <source>Journal of cellular biochemistry</source>, <volume>84</volume>(<issue>1</issue>), <fpage>12</fpage>–<lpage>26</lpage>.</mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schlichting</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Dehne</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Mans</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Endres</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Stuhlmüller</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Sittinger</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kaps</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name><surname>Ringe</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Suitability of porcine chondrocyte micromass culture to model osteoarthritis in vitro</article-title>. <source>Molecular pharmaceutics</source>, <volume>11</volume>(<issue>7</issue>), <fpage>2092</fpage>–<lpage>2105</lpage>.</mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmittgen</surname>, <given-names>T. D.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>E. J.</given-names></string-name>, <string-name><surname>Jiang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sarkar</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Elton</surname>, <given-names>T. S.</given-names></string-name>, &amp; <string-name><surname>Chen</surname>, <given-names>C.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Real-time PCR quantification of precursor and mature microRNA</article-title>. <source>Methods</source>, <volume>44</volume>(<issue>1</issue>), <fpage>31</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymeth.2007.09.006</pub-id></mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmittgen</surname>, <given-names>T. D.</given-names></string-name>, &amp; <string-name><surname>Livak</surname>, <given-names>K. J.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Analyzing real-time PCR data by the comparative CT method</article-title>. <source>Nature Protocols</source>, <volume>3</volume>(<issue>6</issue>), <fpage>1101</fpage>–<lpage>1108</lpage>.</mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmitz</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Laverty</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kraus</surname>, <given-names>V.</given-names></string-name>, &amp; <string-name><surname>Aigner</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2010</year>). <article-title>Basic methods in histopathology of joint tissues</article-title>. <source>Osteoarthritis and Cartilage</source>, <volume>18</volume>, <fpage>S113</fpage>–<lpage>S116</lpage>.</mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname>, <given-names>C. A.</given-names></string-name>, <string-name><surname>Rasband</surname>, <given-names>W. S.</given-names></string-name>, &amp; <string-name><surname>Eliceiri</surname>, <given-names>K. W.</given-names></string-name></person-group> (<year>2012</year>). <article-title>NIH Image to ImageJ: 25 years of image analysis</article-title>. <source>Nature methods</source>, <volume>9</volume>(<issue>7</issue>), <fpage>671</fpage>–<lpage>675</lpage>.</mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwarzbich</surname>, <given-names>M.-A.</given-names></string-name>, <string-name><surname>Gutknecht</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Salih</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Salih</surname>, <given-names>H. R.</given-names></string-name>, <string-name><surname>Brossart</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Rittig</surname>, <given-names>S. M.</given-names></string-name>, &amp; <string-name><surname>Grünebach</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2012</year>). <article-title>The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors</article-title>. <source>Cancer Immunology, Immunotherapy</source>, <volume>61</volume>(<issue>2</issue>), <fpage>193</fpage>–<lpage>202</lpage>.</mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Selim</surname>, <given-names>A. A.</given-names></string-name>, <string-name><surname>Abdelmagid</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Kanaan</surname>, <given-names>R. A.</given-names></string-name>, <string-name><surname>Smock</surname>, <given-names>S. L.</given-names></string-name>, <string-name><surname>Owen</surname>, <given-names>T. A.</given-names></string-name>, <string-name><surname>Popoff</surname>, <given-names>S. N.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2003</year>). <article-title>Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro</article-title>. <source>Critical Reviews™ in Eukaryotic Gene Expression</source>, <volume>13</volume>(<issue>2-4</issue>).</mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheng</surname>, <given-names>M. H.-C.</given-names></string-name>, <string-name><surname>Wergedal</surname>, <given-names>J. E.</given-names></string-name>, <string-name><surname>Mohan</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name><surname>Lau</surname>, <given-names>K.-H. W.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity</article-title>. <source>FEBS letters</source>, <volume>582</volume>(<issue>10</issue>), <fpage>1451</fpage>–<lpage>1458</lpage>.</mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondag</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Mbimba</surname>, <given-names>T. S.</given-names></string-name>, <string-name><surname>Moussa</surname>, <given-names>F. M.</given-names></string-name>, <string-name><surname>Novak</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Jaber</surname>, <given-names>F. A.</given-names></string-name>, <string-name><surname>Abdelmagid</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Geldenhuys</surname>, <given-names>W. J.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Osteoactivin inhibition of osteoclastogenesis is mediated through CD44-ERK signaling</article-title>. <source>Experimental and Molecular Medicine</source>, <volume>48</volume>. <elocation-id>ARTNe257</elocation-id> <pub-id pub-id-type="doi">10.1038/emm.2016.78</pub-id></mixed-citation></ref>
<ref id="c65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname>, <given-names>R.</given-names></string-name>, &amp; <string-name><surname>Lin</surname>, <given-names>L.</given-names></string-name></person-group> (<year>2019</year>). <article-title>Glycoprotein nonmetastatic melanoma protein B (GPNMB) ameliorates the inflammatory response in periodontal disease</article-title>. <source>Inflammation</source>, <volume>42</volume>(<issue>4</issue>), <fpage>1170</fpage>–<lpage>1178</lpage>.</mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Yan</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Yin</surname>, <given-names>W.</given-names></string-name>, &amp; <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Identification of genes associated with osteoarthritis by microarray analysis</article-title>. <source>Molecular Medicine Reports</source>, <volume>12</volume>(<issue>4</issue>), <fpage>5211</fpage>–<lpage>5216</lpage>.</mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tetsunaga</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nishida</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Furumatsu</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Naruse</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hirohata</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yoshida</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Saito</surname>, <given-names>T.</given-names></string-name>, &amp; <string-name><surname>Ozaki</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2011</year>). <article-title>Regulation of mechanical stress-induced MMP-13 and ADAMTS-5 expression by RUNX-2 transcriptional factor in SW1353 chondrocyte-like cells</article-title>. <source>Osteoarthritis and Cartilage</source>, <volume>19</volume>(<issue>2</issue>), <fpage>222</fpage>–<lpage>232</lpage>.</mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname>, <given-names>G. N.</given-names></string-name>, <string-name><surname>Inman</surname>, <given-names>D. M.</given-names></string-name>, <string-name><surname>Dengler-Crish</surname>, <given-names>C. M.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>M. A.</given-names></string-name>, &amp; <string-name><surname>Crish</surname>, <given-names>S. D.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Early pro-inflammatory cytokine elevations in the DBA/2J mouse model of glaucoma</article-title>. <source>Journal of neuroinflammation</source>, <volume>12</volume>, <fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname>, <given-names>Y.-x.</given-names></string-name>, <string-name><surname>Gong</surname>, <given-names>Y.-w.</given-names></string-name>, <string-name><surname>Guo</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lv</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Guo</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Zhuang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>R.</given-names></string-name>, &amp; <string-name><surname>Zhang</surname>, <given-names>X.-z.</given-names></string-name></person-group> (<year>2012</year>). <article-title>Mechanical strain regulates osteoblast proliferation through integrin-mediated ERK activation</article-title>. <source>PLoS ONE</source>, <volume>7</volume>(<issue>4</issue>), <fpage>e35709</fpage>.</mixed-citation></ref>
<ref id="c70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Harkins</surname>, <given-names>L. K.</given-names></string-name>, <string-name><surname>Zubanova</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Harrington</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kovalenko</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Nadeau</surname>, <given-names>R. J.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>P.-Y.</given-names></string-name>, <string-name><surname>Toher</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Lindner</surname>, <given-names>V.</given-names></string-name>, &amp; <string-name><surname>Liaw</surname>, <given-names>L.</given-names></string-name></person-group> (<year>2008</year>). <article-title>Overexpression of Spry1 in chondrocytes causes attenuated FGFR ubiquitination and sustained ERK activation resulting in chondrodysplasia</article-title>. <source>Developmental Biology</source>, <volume>321</volume>(<issue>1</issue>), <fpage>64</fpage>–<lpage>76</lpage>.</mixed-citation></ref>
<ref id="c71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Sondag</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Malcuit</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>M. H.</given-names></string-name>, &amp; <string-name><surname>Safadi</surname>, <given-names>F. F.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Macrophage-Associated Osteoactivin/GPNMB Mediates Mesenchymal Stem Cell Survival, Proliferation, and Migration Via a CD44-Dependent Mechanism</article-title>. <source>Journal of Cellular Biochemistry</source>, <volume>117</volume>(<issue>7</issue>), <fpage>1511</fpage>–<lpage>1521</lpage>.</mixed-citation></ref>
<ref id="c72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Zhuo</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ouyang</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yuan</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>F.</given-names></string-name>, &amp; <string-name><surname>Liu</surname>, <given-names>H.</given-names></string-name></person-group> (<year>2017</year>). <article-title>Glycoprotein non-metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization</article-title>. <source>Cellular immunology</source>, <volume>316</volume>, <fpage>53</fpage>–<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Kong</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Chodosh</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Cao</surname>, <given-names>W.</given-names></string-name></person-group> (<year>2009</year>). <article-title>Anti-inflammatory effect of pigment epithelium-derived factor in DBA/2J mice</article-title>. <source>Molecular vision</source>, <volume>15</volume>, <fpage>438</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107696.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Abu-Amer</surname>
<given-names>Yousef</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Washington University in St. Louis</institution>
</institution-wrap>
<city>St Louis</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Compelling</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Useful</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study offers <bold>useful</bold> findings demonstrating the cartilage-protective effects of osteoactivin in inflammatory experimental models. The study provides <bold>compelling</bold> evidence that osteoactivin may serve as a promising therapeutic target for inflammatory joint diseases.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107696.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>While previous studies by this group and others have demonstrated the anti-inflammatory properties of osteoactivin, its specific role in cartilage homeostasis and disease pathogenesis remains unknown. Building on current knowledge, Asaad and colleagues investigated the functional role of this protein using both in vitro systems and an in vivo post-traumatic osteoarthritis model. In line with existing literature, the authors report that osteoactivin exerts inhibitory effects in these experimental settings. This study thus offers novel evidence supporting the cartilage-protective effects of osteoactivin in various experimental models.</p>
<p>Strengths:</p>
<p>Strengths of the study include its clinical relevance, given the lack of curative treatments for osteoarthritis, as well as the clarity of the narrative and the quality of most results.</p>
<p>Weaknesses:</p>
<p>A limitation of the study is the reliance on standard techniques; however, this is a minor concern that does not diminish the overall impact or significance of the work.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107696.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This manuscript presents compelling evidence for a novel anti-inflammatory function of glycoprotein non-metastatic melanoma protein B (GPNMB) in chondrocyte biology and osteoarthritis (OA) pathology. Through a combination of in vitro, ex vivo, and in vivo models, including the destabilization of the medial meniscus (DMM) surgery in mice, the authors demonstrate that GPNMB expression is upregulated in OA-affected cartilage and that recombinant GPNMB treatment reduces the expression of key catabolic markers (MMPs, Adamts-4, and IL-6) without impairing anabolic gene expression. Notably, DBA/2J mice lacking functional GPNMB exhibit exacerbated cartilage degradation post-injury. Mechanistically, GPNMB appears to mitigate inflammation via the MAPK/ERK pathway. Overall, the work is thorough, methodologically sound, and significantly advances our understanding of GPNMB as a protective modulator in osteoarthritic joint disease. The findings could open pathways for therapeutic development.</p>
<p>Strengths:</p>
<p>(1) Clear hypothesis addressing a well-defined knowledge gap.</p>
<p>(2) Robust and multi-modal experimental design: includes human, mouse, cell-line, explant, and surgical OA models.</p>
<p>(3) Elegant use of DBA/2J GPNMB-deficient mice to mimic endogenous loss-of-function.</p>
<p>(4) Mechanistic insight provided through MAPK signaling analysis.</p>
<p>(5) Statistical analysis appears rigorous, and figures are informative.</p>
<p>Weaknesses:</p>
<p>(1) Clarify the strain background of the DBA/2J GPNMB+ mice: While DBA/2J GPNMB+ is described as a control, it would help to explicitly state whether these are transgenically rescued mice or another background strain. Are they littermates, congenic, or a separate colony?</p>
<p>(2) Provide exact sample sizes and variance in all figure legends: Some figures (e.g., Figure 2 panels) do not consistently mention how many replicates were used (biological vs. technical) for each experimental group. Standardizing this across all panels would improve reproducibility.</p>
<p>(3) Expand on potential sex differences: The DMM model is applied only in male mice, which is noted in the methods. It would be helpful if the authors added 1-2 lines in the discussion acknowledging potential sex-based differences in OA progression and GPNMB function.</p>
<p>(4) Visual clarity in schematic (Figure 7): The proposed mechanism is helpful, but the text within the schematic is somewhat dense and could be made more readable with spacing or enlarged font. Also, label the MAPK/ERK pathway explicitly in panel B.</p>
</body>
</sub-article>
</article>